ANI PHARMACEUTICALS, INC Business Acquisition, Pro Forma Net Income (Loss)
ANI PHARMACEUTICALS, INC (ANIP) reported Business Acquisition, Pro Forma Net Income (Loss) of -$31.74 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2024-02-29
- ANI PHARMACEUTICALS, INC business acquisition, pro forma net income (loss) for the quarter ending 2018-12-31 was $5.47M.
- ANI PHARMACEUTICALS, INC business acquisition, pro forma net income (loss) for the quarter ending 2018-09-30 was $4.46M, a 48.68% decline year-over-year.
- ANI PHARMACEUTICALS, INC business acquisition, pro forma net income (loss) for the quarter ending 2018-06-30 was $2.14M.
- ANI PHARMACEUTICALS, INC business acquisition, pro forma net income (loss) for the quarter ending 2018-03-31 was $1.24M.
- ANI PHARMACEUTICALS, INC business acquisition, pro forma net income (loss) for fiscal 2021 was -$31.74M.
- ANI PHARMACEUTICALS, INC business acquisition, pro forma net income (loss) for fiscal 2020 was -$48.81M.
- ANI PHARMACEUTICALS, INC business acquisition, pro forma net income (loss) for fiscal 2018 was $13.29M.
- ANI PHARMACEUTICALS, INC business acquisition, pro forma net income (loss) for fiscal 2017 was -$3.10M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 3 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month as first filed | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | -$31.74M 10-K · filed 2024-02-29 | ||||||
| 2020-12-31 | -$48.81M 10-K · filed 2023-03-09 | ||||||
| 2018-12-31 | $5.47M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $9.93M derived: sum of 2 quarters · filed 2021-03-11 | $12.07M derived: sum of 3 quarters · filed 2021-03-11 | $13.29M 10-K · filed 2021-03-11 | |||
| 2018-09-30 | $4.46M 10-Q · filed 2019-11-06 | $6.59M derived: sum of 2 quarters · filed 2019-11-06 | $7.81M 10-Q · filed 2019-11-06 | -$5.38M derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2018-06-30 | $2.14M 10-Q · filed 2019-08-07 | $3.37M 10-Q · filed 2019-08-07 | -$9.84M derived: sum of 3 quarters · filed 2021-03-11 | -$1.15M derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2018-03-31 | $1.24M 10-Q · filed 2019-05-09 | -$11.97M derived: sum of 2 quarters · filed 2021-03-11 | -$3.29M derived: sum of 3 quarters · filed 2021-03-11 | ||||
| 2017-12-31 | -$13.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$4.53M derived: sum of 2 quarters · filed 2021-03-11 | -$3.10M 10-K · filed 2021-03-11 | ||||
| 2017-09-30 | $8.68M 10-Q · filed 2018-11-06 | $10.11M 10-Q · filed 2018-11-06 | |||||
| 2013-12-31 | $3.27M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | $4.96M derived: sum of 2 quarters · filed 2016-02-23 | $1.61M derived: sum of 3 quarters · filed 2016-02-23 | $89.00K 10-K · filed 2016-02-23 | |||
| 2013-09-30 | $1.69M 10-Q · filed 2014-11-10 | $1.69M 10-Q · filed 2013-11-07 | -$1.66M derived: sum of 2 quarters · filed 2014-11-10 | -$3.18M 10-Q · filed 2014-11-10 | -$3.18M 10-Q · filed 2013-11-07 | -$7.91M derived: sum of 4 quarters · filed 2014-11-10 | |
| 2013-06-30 | -$3.35M 10-Q · filed 2014-08-07 | -$3.35M 10-Q · filed 2013-08-09 | -$4.87M 10-Q · filed 2014-08-07 | -$4.87M 10-Q · filed 2013-08-09 | -$9.60M derived: sum of 3 quarters · filed 2014-08-07 | -$15.85M derived: sum of 4 quarters · filed 2014-08-07 | |
| 2013-03-31 | -$1.60M 10-Q · filed 2014-05-12 | -$6.25M derived: sum of 2 quarters · filed 2014-05-12 | -$12.50M derived: sum of 3 quarters · filed 2014-05-12 | -$19.42M derived: sum of 4 quarters · filed 2014-05-12 | |||
| 2012-12-31 | -$4.65M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | -$10.90M derived: sum of 2 quarters · filed 2014-02-28 | -$17.82M derived: sum of 3 quarters · filed 2014-02-28 | -$27.72M 10-K · filed 2014-02-28 | |||
| 2012-09-30 | -$6.25M 10-Q · filed 2013-11-07 | -$13.17M derived: sum of 2 quarters · filed 2013-11-07 | -$23.07M 10-Q · filed 2013-11-07 | ||||
| 2012-06-30 | -$6.92M 10-Q · filed 2013-08-09 | -$16.66M 10-Q · filed 2013-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |